- Bydureon pen gets FDA approval
- Study: Participation in diabetes education associated with greater ability to self-manage
- Research Now launches diabetes panel
- Study pinpoints protective genetic mutations for Type 2 diabetes
- Report: Sugar accounts for 17% of normal U.S. diet as Type 2 diabetes accounts for $500 billion in global healthcare spending
CHICAGO — A Type 2 diabetes drug marketed by Eli Lilly and Amylin Pharmaceuticals may lower the risk of cardiovascular disease compared with other diabetes treatments, the two companies said Wednesday.
According to a study presented at the American Heart Association’s scientific sessions in Chicago, use of Byetta (exenatide) was associated with a lower incidence of cardiovascular disease than insulin and several other drug classes.
The study used data from IMS Health’s LifeLink Health Plan Claims Database, comprising medical and pharmaceutical claims for more than 65 million patients from 98 health plans in the United States.
“Heart disease and stroke account for nearly two-thirds of deaths in people with Type 2 diabetes, so it is critically important for us to understand how treatment may affect cardiovascular risk, either positively or negatively,” Amylin SVP and chief medical officer Orville Kolterman said.